21:12 , Jan 27, 2017 |  BC Week In Review  |  Company News

GeoVax Labs, Burnet Institute deal

The biotech partnered with the institute to develop a malaria vaccine by incorporating Plasmodium falciparum and P. vivax sequences identified by the institute with GeoVax's Modified Vaccinia Ankara-Virus-Like Particle (MVA-VLP) vaccine platform. GeoVax said IP...
21:00 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Malaria Mouse studies suggest a two-part vaccination strategy based on a single malaria peptide antigen could help prevent malaria. The vaccination strategy consisted of two stages: immunization with a malarial octapeptide epitope conjugated to...
07:00 , Jun 4, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: HIV reverse transcriptase

Infectious disease INDICATION: HIV / AIDS In vitro studies identified fragments that inhibit HIV reverse transcriptase and could lead to more potent inhibitors of the enzyme to treat HIV/AIDS. In vitro screening of a fragment...
07:00 , Sep 18, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Chris Cain, Associate Editor, and Kai-Jye Lou, Senior Writer RNA sequencing standardized The FDA has convened a consortium to review the status of RNA sequencing for drug development and outline hurdles for incorporating the technology...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Burnet Institute, Artes Biotechnology, Program for Appropriate Technology in Health deal

Burnet Institute and Artes partnered to develop vaccines to prevent transmission of malaria infection from mosquitos to humans. The project has undisclosed funding from the Program for Appropriate Technology in Health (PATH) Malaria Vaccine Initiative...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Company News

Omega Diagnostics Group plc, Burnet Institute sales and marketing update

The institute granted Omega exclusive, worldwide rights to develop and commercialize the Visitect CD4 point-of-care test to determine CD4 counts in HIV patients. The test uses a finger prick to collect a small amount of...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Company News

Burnet Institute diagnostic news

The institute spun-out SeeD4 Pty. Ltd. to develop a rapid point of care diagnostic to monitor levels of CD4+ T cells in HIV patients. The diagnostic is intended for use in developing nations where ELISA...
08:00 , Feb 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Cancer Prostate cancer PIM-1 (PIM1) In vitro and mouse studies identified a mAb against PIM1 that could potentially help treat...
08:00 , Dec 4, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Pulmonary thromboembolism Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) Studies in mice suggest that upregulating CEACAM1 could be useful for...
07:00 , Oct 23, 2006 |  BC Week In Review  |  Company News

Prima BioMed, Macfarlane Burnet Institute for Medical Research and Public Health deal

Under a two-year deal, the institute granted PRR first rights to IP related to ex vivo cell therapies for cancer. The agreement is renewable for an additional two years. If PRR exercises its right to...